Watch for Affirm Holdings (AFRM) to gain at least 15% today. The supplier of BNPL, or buy now, pay later services posted strong fourth-quarter results. It expects to post a profit (in GAAP terms) in Q4/2025.
Affirm expects Q1 GMV (gross merchandise volume) to reach $7.1 billion to $7.4 billion. Revenue of up to $670 million is above expectations. Thanks to adjusted operating margin trends on the rise, Affirm will report a profit soon.
In the software sector, Salesforce (CRM) is today’s hot stock. The firm reported Q2 revenue of $9.33 billion, up by 8.5% Y/Y. It enhanced shareholder returns by repurchasing $4.3 billion in stock in the quarter. It also paid $400 million in dividend payments. In Q3, Salesforce expects revenue of up to $9.36 billion.
Salesforce’s revenue growth forecast below 10% is satisfactory enough to prevent a stock sell-off.
In the drug manufacturing sector, value investors will continue to bid up shares of Bristol-Myers Squibb (BMY) and Gilead Sciences (GILD). After AbbVie (ABBV) and Eli Lilly (LLY) closed higher, investors are betting on the laggards to recover.
Gilead will present at a Wells Fargo healthcare conference on September 4, then at Morgan Stanley’s annual globe healthcare conference on September 5.